

PCT

NOTIFICATION OF ELECTION
(PCT Rule 61.2)

Date of mailing (day/month/year) 30 April 2001 (30.04.01)	To: Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/EP00/05503	Applicant's or agent's file reference SCB525PCT
International filing date (day/month/year) 15 June 2000 (15.06.00)	Priority date (day/month/year) 27 July 1999 (27.07.99)
Applicant MOGNA, Giovanni et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

19 February 2001 (19.02.01)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Athina Nickitas-Etienne Telephone No.: (41-22) 338.83.38
---	---

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07566 A3(51) International Patent Classification⁷: C12N 15/31,
15/74, C12R 1/46, C07K 14/315, A23C 19/032

(21) International Application Number: PCT/EP00/05503

(22) International Filing Date: 15 June 2000 (15.06.2000)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
MI99A001654 27 July 1999 (27.07.1999) IT(71) Applicant (*for all designated States except US*):
ANIDRAL S.R.L. [IT/IT]; Via P. Custodi, 12, I-28100
Novara (IT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MOGNA, Gio-
vanni [IT/IT]; Via P. Custodi, 12, I-28100 Novara (IT).STROZZI, Paolo [IT/IT]; Via P. Custodi, 12, I-28100
Novara (IT). DI LORENZO, Simona [IT/IT]; Via Amendola,
37, I-29100 Piacenza (IT). BOTTAZZI, Vittorio
[IT/IT]; Universita' Cattolica del Sacro Cuore, Via Emilia
Parmense, 84, I-29100 Piacenza (IT). CALLEGARI,
Maria, Luisa [IT/IT]; Universita' Cattolica del Sacro
Cuore, Via Emilia Parmense, 84, I-29100 Piacenza (IT).
MORELLI, Lorenzo [IT/IT]; Universita' Cattolica del
Sacro Cuore, Via Emilia Parmense, 84, I-29100 Piacenza
(IT).(74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Mi-
noja S.r.l., Via Rossini, 8, I-20122 Milano (IT).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,*[Continued on next page]*

(54) Title: PHAGE-RESISTANT MICROORGANISMS AND GENETIC DETERMINANTS OF PHAGE RESISTANCE

(57) Abstract: There are
described bacterial strains,
plasmids derived thereof, a gene
sequence included in the plasmids
encoding a phage resistance
system protein, and a method
to confer phage resistance to
microorganism cultures.

1 2

3 4

WO 01/07566 A3



PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

Published:

— *with international search report*

- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
26 July 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05503

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C12N15/74 C12R1/46 C07K14/315 A23C19/032

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12R C07K A23C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBL, STRAND, MEDLINE, FSTA, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'SULLIVAN T ET AL.: "Structural and functional analysis of pCI65st, a 6.5 kb plasmid from <i>Streptococcus thermophilus</i> NDI-6" MICROBIOLOGY, vol. 145, no. 1, January 1999 (1999-01), pages 127-134, XP000978319 Note: 63.3 % nt sequence identity with SEQ ID NO:1 in 834 nt overlap abstract page 127, right-hand column, line 16-18 page 133, left-hand column, line 30-55 page 133, right-hand column, line 28-33 ----- -/-	1-10

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 February 2001

20/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/EP 00/05503

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR 2 767 831 A (AGRONOMIQUE INST NAT RECH) 5 March 1999 (1999-03-05) Note: 62.4 % nt sequence identity of SEQ ID NO:11 with SEQ ID NO:1 in 929 nt overlap. page 1, line 1 -page 3, line 24 examples 1,4 ---	2,3,10
A	WO 96 21017 A (MOINEAU SYLVAIN ;QUEST INT (NL); VANDENBERGH PETER A (US); VEDAMUT) 11 July 1996 (1996-07-11) page 5, line 28 -page 6, line 26 example 2 ---	2,3,10
A	JANZEN T ET AL.: "Sequencing and characterization of pST1, a cryptic plasmid from Streptococcus thermophilus" FEMS MICROBIOLOGY LETTERS, vol. 74, no. 2-3, 15 August 1992 (1992-08-15), pages 175-180, XP000979636 abstract table 1 ---	3-8
A	ALLISON G E ET AL.: "Phage resistance mechanisms in lactic acid bacteria" INTERNATIONAL DAIRY JOURNAL, vol. 8, no. 3, March 1998 (1998-03), pages 207-226, XP000978412 abstract page 215, line 25-43 page 216, right-hand column, line 22-52 ----	9,10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05503

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR 2767831	A 05-03-1999	AU	9080098 A	22-03-1999
		EP	1007701 A	14-06-2000
		WO	9911803 A	11-03-1999
WO 9621017	A 11-07-1996	US	5824523 A	20-10-1998
		AU	712169 B	28-10-1999
		AU	4497296 A	24-07-1996
		CA	2208107 A	11-07-1996
		EP	0805861 A	12-11-1997
		JP	10512442 T	02-12-1998
		US	5925388 A	20-07-1999
		US	5972673 A	26-10-1999

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SCB525PCT	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/EP00/05503	International filing date (<i>day/month/year</i>) 15/06/2000	Priority date (<i>day/month/year</i>) 27/07/1999
International Patent Classification (IPC) or national classification and IPC C12N1/00		
<p>Applicant ANIDRAL S.R.L.</p> <p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 2 sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application 		

Date of submission of the demand 19/02/2001	Date of completion of this report 03.12.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Barnas, C Telephone No. +49 89 2399 7469



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/05503

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-3,5-23 as originally filed

4 as received on 09/11/2001 with letter of 09/11/2001

Claims, No.:

1-10 as received on 09/11/2001 with letter of 09/11/2001

Drawings, sheets:

1-5 as originally filed

Sequence listing part of the description, pages:

1, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/05503

listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
 the claims, Nos.:
 the drawings, sheets:

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-10
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-10
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-10
	No:	Claims	

2. Citations and explanations
see separate sheet

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D1: O'SULLIVAN T ET AL.: 'Structural and functional analysis of pCI65st, a 6.5 kb plasmid from *Streptococcus thermophilus* NDI-6' MICROBIOLOGY, vol. 145, no. 1, January 1999 (1999-01), pages 127-134, XP000978319

Arts. 33(2)(3) PCT, Novelty and Inventive Step

1. The subject matter of the present set of claims is new over the cited prior art. D1 discloses a gene isolated from *Streptococcus thermophilus* NDI-6 encoding a protein with similarity to the HsdS or specificity proteins from the type 1 restriction-modification systems. The sequence of said gene is, however, different from SEQ ID NO: 1 disclosed in the specification.
2. D1 is the closest prior art for the present application. The difference to D1 is the characterisation of a further gene having the sequence SEQ ID NO: 1 for a protein conferring specificity to the restriction enzyme and methylase in the type 1 restriction-modification system. The cited prior art does not contain any indication that would prompt the skilled person to isolate said gene. SEQ ID NO: 1 and subject matter connected with said sequence, as described in claims 1-10, is, therefore, inventive.

B39 phage-resistant phenotype has, for its use in the dairy-milk field, the same properties as the parental strain; in particular, the acidifying rate in milk is the same as that of the TO03 strain, allowing the use of the B39 strain as starter culture in the same dairy processes in which the parental strain is used.

^{TO03}

The B39 strain has two plasmids, termed pCRB33 and pCRB63, in which two ORFs (Open Reading Frames) were found presenting high homology with the "s" subunits, known to be involved in the type I restriction and modification mechanisms. In the TO03 strains these two ORF are incomplete and thus inactive. The above plasmids can recombine, creating the pCRB96 plasmid, in which the incomplete and inactive ORFs give, upon recombination, a complete and active "s" subunit.

The pCRB33, pCRB63, and pCRB96 plasmids are further embodiments of the invention.

Such plasmids are described in the following example 1. In particular, the complete restriction map is provided for each plasmid.

In another aspect, the invention relates to the gene determinant responsible for conferring phage resistance. This determinant corresponds to the ORF of pCRB96 plasmid, encoding the above mentioned "s" subunit, whose sequence is reported in SEQ ID N: 1. Such a protein, in the type I restriction and modification systems, confers specificity to the restriction enzyme and methylase.

The subunit alone is not able to confer phage resistance; actually transferring it to a heterologous host does not automatically determine phenotype change, the presence of gene encoding the two involved enzymes being necessary. The introduction in a host containing a complete type I R/M of a heterologous s subunit, may result in an enhanced phage resistance, comparable to a complete R/M system. In fact, the s subunit alone can change the system specificity, without inhibiting the pre-existing one. Resistance results from the sum of the effects of the two subunits.

CLAIMS

1. *Streptococcus thermophilus* strains deposited at BCCM/LMG (Gent/Belgium) P-18383 and P-18384.
 - 5 2. Nucleic acid molecule having the sequence Seq. ID N°. 1.
 3. Plasmid containing the nucleic acid molecule of claim 2.
 4. Plasmid obtainable from a culture of *Streptococcus thermophilus* strain N. P-18384 according to claim 1, having 3375 base pairs and a single restriction site for each AccI, Asel, AsnI, EcoRV, FokI, NotI, PstI, Pvull, XbaI nuclease.
 - 10 5. Plasmid obtainable from a culture of *Streptococcus thermophilus* strain N. P-18384 according to claim 1, having 6184 base pairs and a single restriction site for each Aval, HindIII, KpnI, Pvul, SacI, SacII, Sall, SpeI, SphI nuclease.
 6. Plasmid obtainable from a culture of *Streptococcus thermophilus* strain N. P-18383 according to claim 1, having 9515 base pairs and a single restriction site for each Aval, NotI, PstI, Pvul, Pvull, SacI, SacII, Sall, SphI nuclease.
 - 15 7. Microorganism containing the plasmid of claims 3-6.
 8. Microorganism according to claim 7, selected from *Streptococcus thermophilus*, *Lactobacillus lactis*, *Bacillus subtilis*, *Escherichia coli*, *Lc. lactis* subsp. *lactis*, *Lc. lactis* subsp. *diacetylactis*, *Lc. Cremonis*, *Lb. delbrueckii* subsp. *Lactis*, *Lb. delbrueckii* subsp. *bulgaricus*, *Lb. delbrueckii* subsp. *delbrueckii*, *Lb. Helveticus*, *Lb. casei*.
 - 20 9. Starter culture for milk fermentation, comprising a microorganism of claims 1, 7 or 8.
 10. Use of a plasmid of claims 3-6, alone or in combination with a conjugative plasmid, for conferring phage resistance to a bacterium.
- 3 and 6

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07566 A2

- (51) International Patent Classification⁷: C12N 1/00 Sacro Cuore, Via Emilia Parmense, 84, I-29100 Piacenza (IT).
- (21) International Application Number: PCT/EP00/05503
- (22) International Filing Date: 15 June 2000 (15.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
MI99A001654 27 July 1999 (27.07.1999) IT
- (71) Applicant (*for all designated States except US*): ANIDRAL S.R.L. [IT/IT]; Via P. Custodi, 12, I-28100 Novara (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MOGNA, Giovanni [IT/IT]; Via P. Custodi, 12, I-28100 Novara (IT). STROZZI, Paolo [IT/IT]; Via P. Custodi, 12, I-28100 Novara (IT). DI LORENZO, Simona [IT/IT]; Via Amendola, 37, I-29100 Piacenza (IT). BOTTAZZI, Vittorio [IT/IT]; Universita' Cattolica del Sacro Cuore, Via Emilia Parmense, 84, I-29100 Piacenza (IT). CALLEGARI, Maria, Luisa [IT/IT]; Universita' Cattolica del Sacro Cuore, Via Emilia Parmense, 84, I-29100 Piacenza (IT). MORELLI, Lorenzo [IT/IT]; Universita' Cattolica del
- (74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/07566 A2

(54) Title: PHAGE-RESISTANT MICROORGANISMS AND GENETIC DETERMINANTS OF PHAGE RESISTANCE

(57) Abstract: There are described new bacterial strains, plasmids derived thereof, a gene sequence included in the plasmids encoding a phage resistance system protein, and a method to confer phage resistance to microorganism cultures.

PHAGE-RESISTANT MICROORGANISMS AND GENETIC DETERMINANTS OF PHAGE RESISTANCE

The present invention relates to novel bacterial strains, the plasmids derived thereof, a gene sequence included in the plasmids, encoding a protein of the phage resistance system, and a method to confer such a resistance to microorganism cultures.

5 INVENTION BACKGROUND

Lactic bacteria have a fundamental role in the manufacturing process of milk derivatives, particularly of the fermented milks and cheeses.

Their action takes place in the first phases of cheese transformation, inducing some modifications in the milk and/or in the curd, depending on the 10 production rate and amount of lactic acid obtained from lactose fermentation.

The acidifying capacity and total enzyme activity of the lactic bacteria starter culture, used in specific dairy manufacturing steps, are fundamental technological parameters, which determine the organoleptic and structural characteristics of the finished product.

15 These metabolic properties are typical of the different species of lactic bacteria and depend, quantitatively, in different ways, on the number and the degree of vitality of the lactic bacteria in the culture and on their multiplication rate in milk and subsequently in curd.

A delay or even worse, a block in the growth starter, can cause serious 20 manufacturing problems, impairing the industrial process as a whole.

A more frequent cause of slowed down or completely blocked bacterial replication is due to the presence of bacteriophages, viruses able to replicate inside a bacterial cell. Bacteriophages, or phages, are able to recognize and specifically attack the host cell and, in the lytic cycle, to totally destroy it, 25 releasing dozens or hundreds of other virulent phages able to attack other

sensitive bacterial cells.

The event, first described in 1935, constitutes to date, one of the most serious problems affecting the cheese industry because when the phage infection starts, the possibility arises that production cannot be completed thus determining huge economic loss.

The most promising results for overcoming this problem have been achieved using bacterial cultures comprised of:

- a) strains with different lysotype (phage sensitivity) used in rotation;
- b) phage-resistant strains.

The first solution, at the moment the most adopted by the starter-producing companies, involves considerable organization efforts from culture providers and users, and, in any case, does not permit a complete standardization of the finished product. This is because it is almost impossible to obtain, to isolate, and to produce bacterial strains with identical technological characteristics but with a different lysotype.

The second solution can be obtained by different mechanisms.

The phage-resistant strains arise spontaneously in sensitive populations following phage attack.

The phage-resistance mechanisms outlined in these strains can be grouped into three categories:

1. block of adsorption on the bacterial wall and subsequent block of the phage DNA entry in the cytoplasm;
2. phage DNA restriction (enzyme cleavage) upon entry inside the bacterial cell;
3. interference with the phage DNA duplication mechanisms upon its entrance inside the bacterial cell (abortive infection).

However, spontaneous phage-resistant mutants are generally characterized by a scarce technological aptitude, making them unsuitable for

industrial use (King W.R. et al., Appl. Environ. Microbiol., 1983, 45, 1481-1485; Steenson L.R. et al., Dairy Sci., 1986, 69, 2227-2236).

Recently inventions have been described which deal with the problem of obtaining phage-resistant strains with high technological properties by means of 5 genetic engineering aimed at introducing genes encoding one or more of the above listed mechanisms in starter strains (patents US-5,824,523 and US-5,538,864).

This approach presents some drawbacks from the industrial point of view because these microorganisms and the foods obtained therefrom are included, at 10 least in the European Community, in the "Novel Foods" category, governed by the EC regulation N°. 258/97 of January, 27, 1997.

The possibility to obtain phage-resistant culture strains by using natural gene transfer techniques is of particular interest.

For this purpose it is necessary to select genetic elements able to 15 recombine and mobilize in vivo and to contemporarily confer elevated phage resistance levels.

DESCRIPTION OF THE INVENTION

The authors of the present application isolated novel *Streptococcus thermophilus* strains showing phage-resistance. These strains were 20 taxonomically, technologically, and genetically characterized. Furthermore, gene elements responsible for the phage resistance were isolated and characterized.

The parental strain, called TO03, was deposited at the BCCMTM/Img Bacteria Collection (Gent-Belgio) at N. P-18384, whilst the corresponding phage-resistant mutant, termed B39, was deposited at the same collection at N. P-25 18383. Both strains represent the first aspect of the invention. These strains contain the gene information conferring phage resistance, but only in the B39 strain, in which the two plasmids - otherwise contained as two distinct molecules in the wild type – are genetically recombined, phage resistance is observed. The

B39 phage-resistant phenotype has, for its use in the dairy-milk field, the same properties as the parental strain; in particular, the acidifying rate in milk is the same as that of the TO03 strain, allowing the use of the B39 strain as starter culture in the same dairy processes in which the parental strain is used.

5 The B39 strain has two plasmids, termed pCRB33 and pCRB63, in which two ORFs (Open Reading Frames) were found presenting high homology with the "s" subunits, known to be involved in the type I restriction and modification mechanisms. In the TO03 strains these two ORF are incomplete and thus inactive. The above plasmids can recombine, creating the pCRB96 plasmid, in
10 which the incomplete and inactive ORFs give, upon recombination, a complete and active "s" subunit.

The pCRB33, pCRB63, and pCRB96 plasmids are further embodiments of the invention.

Such plasmids are described in the following example 1. In particular, the
15 complete restriction map is provided for each plasmid.

In another aspect, the invention relates to the gene determinant responsible for conferring phage resistance. This determinant corresponds to the ORF of pCRB96 plasmid, encoding the above mentioned "s" subunit, whose sequence is reported in SEQ. ID N. 1. Such a protein, in the type I restriction and
20 modification systems, confers specificity to the restriction enzyme and methylase.

The subunit alone is not able to confer phage resistance; actually transferring it to a heterologous host does not automatically determine phenotype change, the presence of gene encoding the two involved enzymes being necessary. The introduction in a host containing a complete type I R/M of a heterologous s
25 subunit, may result in an enhanced phage resistance, comparable to a complete R/M system. In fact, the s subunit alone can change the system specificity, without inhibiting the pre-existing one. Resistance results from the sum of the effects of the two subunits.

The gene determinant can be inserted in any suitable plasmid using conventional techniques (for example as described in Maniatis, T. et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 1982).

5 A plasmid containing the gene determinant for phage resistance described herein is another object of the invention.

The non-conjugative plasmids, such as pCRB96, can be used in conjunction with other plasmids able to mediate their transfer. Therefore, in another aspect, the invention relates to the use of plasmids containing the gene determinant of phage resistance described herein, alone or in combination with a 10 conjugative plasmid, to confer phage resistance to bacteria.

Another aspect of the invention relates to a host microorganism in which the plasmid containing the phage resistance gene determinant, in accordance with the invention, is able to replicate. The plasmid can be introduced by conventional techniques, such as conjugative transfer and transformation.

15 Besides *Streptococcus thermophilus*, the host can be *Bacillus subtilis* or *Escherichia coli*, or preferably *Lactococcus lactis*. The introduction by transformation of the s subunit in a heterologous host of genera and species other than *Streptococcus thermophilus*, but endowed with the same industrial interest, can be accomplished by vectors suitable for the host itself. The 20 microorganisms containing the plasmid of the invention are particularly useful in the production of milk derivative such as fermented milks and cheeses. They are used as starter cultures, comprised of single or multiple strains.

DETAILED DESCRIPTION OF THE INVENTION

25 The *Streptococcus thermophilus* TO03 strain, used as starter culture in the fresh and pasta filata cheeses, proved to be sensitive to the lytic bacteriophage SST3 attack.

The TO03 strain was characterized by:

- taxonomy, obtained by hybridization with a 23 S rRNA specific

probe according to Ehmann et al., 1992 (Fig. 1);

- sugar fermentation profile, obtained by API tunnels, which was positive to glucose, fructose, lactose and sucrose;
- acidifying capacity in sterile skim milk at 37°C, as determined by continuous pH detection (Fig. 2);
- two extra-chromosomal DNA or plasmids, 3,3 and 6,3 kb in size, named pCRB33 and pCRB63, respectively (Fig. 3).

The TO03 strain was attacked by the SST3 lytic phage, with a phage/bacterial cell ratio of 1:10 (m.o.i. 0,1). The surviving cells were plated on M17 agar medium. The plates were then incubated under anaerobiosis at 42°C overnight. This procedure allowed the identification of 40 colonies of the original bacterial population, constituted of 10⁹ CFU/ml. The isolated colonies were further assayed for phage resistance.

Also the obtained phage-resistant isolates were characterized by their sugar fermentation profile, their acidifying capacity in milk and extra-chromosomal DNA content.

Thus the resistant phage isolates could be divided into two groups:

- Group R1 comprising isolates containing the two plasmids, pCRB33, pCRB63 and the additional pCRB96 plasmid.
- Group R2 comprising isolates containing the pCRB33 and the additional pCRB96 plasmid.

All isolates were taxonomically identical to the parental strain, showed the same sugar fermentation profile, but grew more slowly in milk, making them of low technological usefulness.

An isolate of the R2 group was successively grown in liquid M17 at 30°C, a temperature lower than the optimal one. The bacterial population obtained in these conditions was plated on agar medium and further subjected to phage attack.

The CFU, that proved to be stably phage-resistant, about 50% of the isolates, were thus again tested in order to evaluate their acidifying rate in milk. Surprisingly, in one of these colonies, termed B39, an acidifying rate similar to that of the parental strain was observed (Fig. 2).

5 The plasmid profile analysis of this strain demonstrated the presence of the 9,6 kb plasmid, termed pCRB96, alone.

In order to study the involvement of the pCRB96 plasmid in phage resistance, we proceeded to the curing of the plasmid itself. The obtained clone, termed C48, was free of plasmids and SST3 phage sensitive. In order to obtain a further confirmation of the role of this plasmid, we proceeded to reintroduce it by conjugation into the C48 clone. However the C48 clone had the same phenotypic characters as the B39 strain, making discrimination between donors and recipients after the conjugation impossible. To overcome this drawback we selected a fusidic acid-resistant clone, starting from C48.

15 The C48 strain was UV irradiated and the surviving cells were seeded in M17 agar medium, containing fusidic acid. The aim was to select a mutant to this type of antibiotic in order to use it as a recipient selector after conjugation.

The obtained clone was named TO60.

20 The UV rays did not alter the clone SST3 phage sensitivity. Because the pCRB96 plasmid is conjugative, it was necessary to perform a co-transfer of the plasmid itself mediated by pAM β 1. This is a conjugative plasmid and it encodes erithromycin resistance. The subsequent steps, aimed at obtaining the plasmid transfer, are illustrated in Fig. 4 and can be summarized as follows:

25 - the pAM β 1 plasmid was transferred from the donor strain *Lactobacillus lactis* subsp. *lactis* SH4174, to the B39 clone by a first conjugation. The colonies of this donor strain were counted in M17 plates containing glucose and erithromycin, and incubated at 30°C under anaerobic conditions. The trans-conjugating colonies were selected on M17 plates containing lactose and

erithromycin and incubated at 42°C in anaerobic conditions;

5 - in a second conjugation event we used the B39 clone (containing pAM β_1) as the donor strain and the TO60 clone as the recipient strain. In this case, the expected trans-conjugants were resistant to erithromycin and also to fusidic acid. All the colonies with these characteristics were assayed for phage resistance.

Some of them (11 over a total of 350 assayed colonies) proved to be phage resistant. The plasmid content of these clones demonstrated the contemporary presence of the pAM β_1 and the pCRB96 plasmids.

10 The curing experiments and the pCRB96 plasmid transfer have thus demonstrated that the phage resistance of the clones isolated starting from the TO03 strain was linked to the presence of such plasmid.

15 The phage-resistant clones did not show full resistance against the SST3 phage, but the number of the phage plaques obtained on the plate was reduced compared to the PFU number obtained with the TO03 strain of at least 2 log. In order to identify the type of phage resistance involved, we performed cross-hybridizations between the SST3 phage propagated in the TO03 strain, and the same phage propagated in the B39 strain.

For convenience the latter phage was called SST39.

20 As demonstrated in table 1 the phage titrated on the sensitive strain, showed a higher titre than that obtained when the host strain was B39. On the other hand the phage multiplied on the B39 strain produced the same PFU/ml when titrated on the two strains.

Table 1

Host strain	SST3 phage	SST39 phage
	PFU/ml	PFU/ml
TO03	2×10^8	3×10^7
B39	3×10^6	3×10^7
C48	2×10^8	3×10^7

Table 2 outlines the results of the titrations obtained on the sensitive strains and on the strain resistant to the SST39 propagated on TO03 and B39, respectively. It is possible to observe that the SST39 phage lost its ability to attack with high efficiency the phage resistant strain upon propagation on the TO03 strain. This behavior is typical of restriction and modification systems. We thus attributed a role in an R/M system to the pCRB96 plasmid.

10

Table 2

Host strain	SST39/TO03 phage	SST39/B39 phage
	PFU/ml	PFU/ml
TO03	2×10^7	3×10^8
B39	3×10^5	3×10^8
C48	2×10^7	3×10^8

Plasmid DNA analysis

15

The restriction map analysis of the pCRB33, pCRB63, and pCRB96 plasmids suggested that the latter could be the result of the integration of the two plasmids originally located in the TO03 phage-resistant strain. The first confirmations were obtained in DNA/DNA hybridization experiments. With the latter method, in fact, signals were obtained when the pCRB96 plasmid was hybridized to probes comprised of pCRB33 and pCRB63 fragments.

20

In order to obtain further evidence of the integration event we conducted cloning and sequencing of the pCRB33 plasmid. The plasmid graphic

representation is shown in Fig. 5. From the sequence analysis we could localize two complete ORFs, indicated in fig. 5 ORF1 and ORF2, respectively.

The ORF2 showed a high homology (87%) with respect to the sequence of the RepA protein, located on the pST1 plasmid of the Streptococcus thermophilus ST strain (deposit number GENE BANK X65856). A termination region was found downstream from the coding region, constituted of repeated sequences with 86% homology compared to that of the above mentioned RepA. The ORF1 shows homology in some portions to many s subunits of type I restriction and modification system.

The higher homologies were found in a 133 bp region whose sequence contains one of the two conserved motifs from the s subunits. The same homology to the s subunits was found also in a region of 153 bp outside the ORF1 and 473 bp distant from the end of the first region. These two regions can be considered two repeated direct sequences. We named the first 133 bp sequence DR1, and the second 153 bp sequence DR2.

Using a primer set designed on the sequence of the two DR found in pCRB33, the pCRB96 plasmid was amplified by PCR. The amplification product was made up of two fragments of 3,3 and 6,3 kb, respectively. These results induced us to hypothesize that the two DRs would be located in the integration region.

In summary pCRB33 contains a gene encoding a protein responsible for replication and probably two DR involved in the integration event.

We thus cloned and determined the nucleotide sequence of the pCRB63 plasmid. The sequence analysis did not show any homology to the known genes encoding for phage resistance apart from the ORF1, whose sequence showed a region endowed with high homology with respect to the different s subunit of type I restriction and modification systems, exactly as previously demonstrated for the pCRB33 plasmid ORF1. The revealed homology also in this case concerned the

conserved motifs of the s subunits. Also in the pCRB63 plasmid are present the two DR, exactly as for pCRB33.

The pCRB96 plasmid was thus fully sequenced and resulted to be a co-integration product of the pCRB33 and pCRB63 plasmids.

5 The two regions in which the integration takes place are those delimited by the two DRs, whilst the region between them is where the two plasmids are cut and joined together. In fact, in pCRB96 there are 2 regions in which DR1 and DR2 are present. The pCRB33 DR1 is, in this case, associated with the pCRB63 DR2, whilst the smaller plasmid DR2 is associated with the pCRB63 DR1.

10 The ORF1 (Fig. 2), with high homology to the s subunits of type 1 R/M systems, in particular to the s subunit isolated from *Lactobacillus lactis* IL-1403 and the s subunit of *Lldl* of *Lactococcus lactis* subsp. *cremoris* (deposit number GENE BANK AF 034786 and U90222) which are 55% homologous, was located in one of the integration regions. In the case of pCRB96, the sequence, 15 homology, and phenotype demonstrate that the s subunit encoding gene is complete and functional.

On the contrary, pCRB33 and pCRB63 contain ORFs with homology to genes encoding the s subunit of type I R/M systems, but they are incomplete and thus not functional. Only pCRB96, by means of integration, has the functional 20 gene, whose sequence is the sum of pCRB33 ORF1 and pCRB63 ORF1 portions. The sequence of the entire pCRB96 s subunit is reported in Seq ID N°.

1.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Taxonomic identification of the TO03 and B39 strains

25 Probe used: CATGCCTTCGCTTACGCT

Probe and hybridization protocol according to Ehrmann et al. (1992) "Species-specific oligonucleotide probe for the identification of *Streptococcus thermophilus*", Systematic and Applied Microbiology, 15, 453-455.

Hybridization results:

A1: Model strain of the species *Streptococcus thermophilus* DSM 20617 (positive control);

A2: DNA extracted from *Lactobacillus helveticus* ATCC 15009 (negative control);

5 B1: DNA extracted from *Streptococcus thermophilus* B39;

B2: DNA extracted from *Streptococcus thermophilus* TO03.

Positive signals were obtained from the reference strain DSM 20617 and from the TO03 and B39 strains under investigation, thus confirming to be *Streptococcus thermophilus* species.

10 **Figure 2:** Acidification curve: 1% inoculum, sterile skim milk, 37°C.

Figure 3: Plasmid profile of the TO03 (well 2) and B39 (well 4) strains.

Figure 4: Scheme of the conjugations performed in order to co-transfer pAMβ1 and pCRB96 plasmids.

Figure 5: Schematic representation of pCRB33.

15 ORF1: ORF located from nt 411 to nt 1308, corresponding to 299 amino acids, of the appended pCRB33 nucleotide sequence. This ORF shows homology to different subunits of type I restriction systems.

ORF2: ORF located from nt 2070 to nt 2960. This ORF shows 87% homology to the pST1 RepA (acc. num. X65856).

20 The following examples illustrate the invention in further detail.

EXAMPLE 1

Characterization of the pCRB33, pCRB63, and pCRB96 plasmids.

The following tables report the restriction profiles of the pCRB33, pCRB63, and pCRB96 plasmids.

Table 3: pCRB33 plasmid, 3375 base pairs:

Enzyme name	N°. cuts	Site positions	Recognition sequence
Accl		1233	gt/mkac
Alul		134 138 161 466 622 1137 1670 1714 2259 2421 2745 2932 2982	ag/ct
Asel		2055	at/taat
Asnl		2055	at/taat
Avall		2199 2213 2227	g/gwcc
Ddel		157 1144 1215 1671 1695 2159 2203 2255	c/tnag
DpnI		985 2253	ga/tc
DraI		2828 3024	ttt/aaa
EcoRI		39 1804	g/aattc
EcoRV		636	gat/atc
FokI		259	ggatg
HaeIII		2157 2173 3092 3275	gg/cc
HindIII		1712 2257 2743	a/agctt
HinfI		1223 1697 2006 2102 2341	g/antc
HpaII		202-2174	c/cgg
KpnI		1565	ggta/c
Mael		135 139 669 733 784 1877 2848 2854 3084 3269 3277	c/tag
Maell		1081 1201 1468 2887 3049 3174 3306	a/cgt

(continued)

Table 3 (continued)

Enzyme name	Nº. cuts	Site positions	Recognition sequence
MaeIII	8	712 1082 1177 1752 2499 2872 3045 3307	/gtnac
MboI	2	983 2251	/gatc
MseI	23	8 167 237 243 287 335 358 518 616 1095 1329 1904 1996 2055 2195 2378 2447 2636 2741 2827 2965 3023 3180	t/taa
NotI	1	3090	gc/ggccgc
PstI	1	3101	ctgca/g
PvuII	1	2421	cag/ctg
Sau3AI	2	983 2251	/gatc
Sau96I	3	2199 2213 2227	g/gncc
SpeI	2	1876 3083	a/ctagt
TaqI	12	1 632 638 763 1254 1735 1849 2004 2111 2985 3104 3372	t/cga
XbaI	1	732	t/ctaga

wherein:

r = a or g; k = g or t; h = a or c or t; d = a or g or t; y = c or t; s = c or g; b = c or g
or t; n = a or c or g or t; m = a or c; w = a or t; v = a or c or g.

The following endonucleases did not cleave the pCRB33 sequence:

ApaI, Ava I, BamHI, BclI, BglI, Cfol, Clal, HaeII, HinclI, HindIII, HpaI, Ncol, Pvul,
SacI, SacII, Sall, Smal, Sohl, Xhol, Xmal.

Table 4: pCRB63 plasmid, 6148 base pairs:

Enzyme name	N°. cuts	Site positions	Recognition sequence
Accl	4	165 312 2451 4102	gt/mkac
Alul	20	692 850 1358 1487 1518 1965 2264 2270 2471 2625 2913 3155 3667 3717 3744 3793 4038 4270 4648 5530	ag/ct
Asel	2	81 5115	at/taat
Asnl	2	81 5115	at/taat
Aval	1	2702	c/yccrg
Avall	2	200 4368	g/gwcc
Cfol	8	1203 1897 2046 2609 2909 4097 4442 4483	gcgc/c
Clal	2	276 322	at/cgat
Ddel	11	61 120 346 1930 2130 3953 4251 4276 4581 5002 5904	c/tnag
DpnI	7	363 1029 1067 4890 5032 5718 5917	ga/tc
DraI	5	922 2773 4304 5261 5483	ttt/aaa
EcoRI	2	1569 3413	g/aattc
EcoRV	2	274 2510	gat/atc
FokI	6	3875 3905 3911 4961 5500 5565	ggatg
HaeII	2	1898 4098	rgcgc/y
HaeIII	3	2189 3001 5891	gg/cc
HincII	2	2452 3706	gtt/rac

(continued)

Table 4 (continued)

Enzyme name	Nº. cuts	Site positions	Recognition sequence
HindII	2	2452 3706	gty/rac
HindIII	1	2623	a/agctt
HinfI	12	124 324 344 380 612 1434 2146 2453 3955 4255 5355 5448	g/antc
HpaII	3	194 3396 5812	c/cgg
KpnI	1	580	ggta/c
MaeI	16	609 1580 1916 2271 2540 2721 2910 3597 4079 4122 4184 4622 4985 5231 5272 5945	c/tag
Maell	19	88 211 355 877 1529 2092 2318 2545 2827 2877 3283 3349 3367 3624 3686 3887 3987 4192 6016	a/cgt
Maelli	12	240 341 1094 1260 2011 2273 2878 3350 3590 4056 4773 5379	/gttnac
MboI	7	361 1027 1065 4888 5030 5716 5915	/gatc
MseI	44	81 99 147 207 375 921 1062 1151 1481 2219 2410 2711 2772 3020 3092 3204 3221 3443 3491 3544 3644 3694 3750 3825 3937 3993 4003 4141 4229 4303 4407 4530 4550 4750 4847 5015 5115 5260 5455 5482 5548 5626 5630 5666	t/taa
PvuI	1	364	cgat/cg

(continued)

Table 4 (continued)

Enzyme name	N°. cuts	Site positions	Recognition sequence
Sacl	1	3795	gagct/c
SacII	1	2020	ccgc/gg
Sall	1	2450	g/tcgac
Sau3AI	7	361 1027 1065 4888 5030 5716 5915	/gatc
Sau96I	3	200 4368 5889	g/gncc
Spel	1	4183	a/ctagt
SphI	1	5743	gcatg/c
TaqI	13	276 322 2377 2451 2465 2473 2620 2808 2866 3377 3726 4666 5921	t/cga
XbaI	4	608 2720 4078 4121	t/ctaga

r = a or g; k = g or t; h = a or c or t; d = a or g or t; y = c or t; s = c or g; b = c or g

5

or t; n = a or c or g or t; m = a or c; w = a or t; v = a or c or g.

The following endonucleases did not cleave the pCRB33 sequence:

Apal, BamHI, BclI, BglI, HpaI, NcoI, PstI, PvuII, SmaI, XbaI, XmaI.

10

15

Table 5: pCRB96 plasmid, 9515 base pairs:

Enzyme name	N°. cuts	Site positions	Recognition sequence
Accl	5	1150 1297 3436 5087 7381	gt/mkac
Alul	33	134 138 161 466 622 1677 1835 2343 2472 2503 2950 3249 3255 3456 3610 3898 4140 4652 4702 4729 4778 5023 5255 5633 6515 7284 7815 7859 8402 8564 8888 9072 9122	ag/ct
Asel	3	1066 6100 8200	at/taat
Asnl	3	1066 6100 8200	at/taat
Aval	1	3687	c/ycgrrg
Avall	5	1185 5353 8342 8356 8370	g/gwcc
Cfol	8	2188 2882 3031 3594 3894 5082 5427 5468	gcg/c
Clal	2	1261 1307	at/cgat
Ddel	18	157 1046 1105 1331 2915 3115 4938 5236 5261 5566 5987 6889 7363 7816 7840 8302 8346 8398	c/tnag
DpnI	9	1348 2014 2052 5875 6017 6703 6902 7132 8396	ga/tc
DraI	7	1907 3758 5289 6246 6468 8969 9164	ttt/aaa
EcoRI	4	39 2554 4398 7949	g/aattc
EcoRV	3	636 1259 3495	gat/atc

(continued)

Table 5 (continued)

Enzyme name	Nº. cuts	Site positions	Recognition sequence
FokI	7	259 4860 4890 4896 5946 6485 6550	ggatg
HaeII	2	2883 5083	rgcgc/y
HaeIII	7	3174 3986 6876 8300 8316 9232 9415	gg/cc
HincII	2	3437 4691	gtt/rac
HindII	2	3437 4691	gtt/rac
HindIII	4	3608 7857 8400 8886	a/agctt
HinfII	17	1109 1309 1329 1365 1597 2419 3131 3438 4940 5240 6340 6433 7371 7842 8151 8245 8484	g/antc
HpaII	5	202 1179 4381 6797 8317	c/cgg
KpnI	2	1565 7710	ggta/c
MaeI	27	135 139 669 733 784 1594 2565 2901 3256 3525 3706 3895 4582 5064 5107 5169 5607 5970 6216 6257 6930 8022 8988 8994 9224 9409 9417	c/tag
Maell	26	1073 1196 1340 1862 2514 3077 3303 3530 3812 3862 4268 4334 4352 4609 4671 4872 4972 5177 7001 7228 7349 7614 9027 9189 9314 9446	a/cgt

(continued)

Table 5 (continued)

Enzyme name	N°. cuts	Site positions	Recognition sequence
MaeIII	21	712 1225 1326 2079 2245 2996 3258 3863 4335 4575 5041 5758 6364 7229 7325 7897 8415 8642 9012 9185 9447	/gtnac
MboI	9	1346 2012 2050 5873 6015 6701 6900 7130 8394	/gatc
MseI	68	8 167 237 243 287 335 358 518 616 1066 1084 1132 1192 1360 1906 2047 2136 2466 3204 3395 3696 3757 4005 4077 4189 4206 4428 4476 4529 4629 4679 4735 4810 4922 4978 4988 5126 5214 5288 5392 5515 5535 5735 5832 6000 6100 6245 6440 6467 6533 6611 6615 6651 7242 7291 7475 8049 8141 8200 8338 8521 8590 8779 8884 8968 9105 9163 9320	t/taa
NotI	1	9230	gc/ggccgc
PstI	1	9241	ctgca/g
PvuI	1	1349	cgt/cg
PvuII	1	8564	cag/ctg
SacI	1	4780	gagct/c
SacII	1	3005	ccgc/gg
Sall	1	3435	g/tcgac
Sau3AI	9	1346 2012 2050 5873 6015 6701 6900 7130 8394	/gatc
Sau96I	6	1185 5353 6874 8342 8356 8370	g/gncc
Spel	3	5168 8021 9223	a/ctagt
SphI	1	6728	gcatg/c

(continued)

Table 5 (continued)

Enzyme name	N°. cuts	Site positions	Recognition sequence
TaqI	23	1 638 1261 1307 3362 3436 3450 3458 3605 3793 3851 4362 4711 5651 6906 7402 7880 7994 8149 8254 9125 9244 9512	t/cga
XbaI	5	732 1593 3705 5063 5106	t/ctaga

r = a or g; k = g or t; h = a or c or t; d = a or g or t; y = c or t; s = c or g; b = c or g or t; n = a or c or g or t; m = a or c; w = a or t; v = a or c or g.

5 The following endonucleases did not cleave the pCRB96 sequence:

Apal, BamHI, BclI, BglI, HpaI, NcoI, SmaI, XbaI, XmaI.

EXAMPLE 2

Conjugative transfers

1. In the first conjugation cycle, the cultures of the donor strain *Lactobacillus*

10 *lactis* SH4174 containing the pAMβ1 plasmid encoding erythromycin resistance, and cultures of the recipient strains *Streptococcus thermophilus* B39, containing the pCRB96 plasmid, are grown.

2. In the second conjugation cycle, the donor and recipient strain cultures of

Streptococcus thermophilus B39 (pAMβ1) containing the pAMβ1 plasmid and the

15 pCRB96 plasmid, and of *Streptococcus thermophilus* TO60, plasmid-free and resistant to fusidic acid, respectively, are grown.

Procedure

Equal volumes are taken from both cultures and mixed.

From this mix 0,2 ml are taken, placed on a Petri dish containing M17 medium without any selection agent, uniformly plated, and incubated from 6 to 30 hours.

The bacterial cells grown on this medium are harvested with 1 ml of saline

and then appropriate decimal dilutions, in culture media (see table) suitable for selecting donor and recipient strains, and possible trans-conjugants present in the conjugation mix, were seeded on plate.

Table 6: First conjugation cycle.

5

	STRAINS	SELECTION
DONORS	SH4174	30°C, 50 µg/ml erithromycin, glucosate M17 medium
RECIPIENT S	B39 (pCRB96)	42°C, lactosate M17 medium
TRANS-CONJUGATES	B39 (pCRB96-pAMβ1)	42°C, lactosate M17 medium, 10 µg/ml erithromycin

Table 7: Second conjugation cycle.

	STRAINS	SELECTION
DONORS	B39 (pCRB96-pAMβ1)	42°C, lactosate M17 medium, 10 µg/ml erithromycin
RECIPIENTS	TO60	42°C, lactosate M17 medium, 10 µg/ml fusidic acid
TRANS-CONJUGATES	TO60 (pCRB96-pAMβ1)	42°C, lactosate M17 medium, 10 µg/ml erithromycin, 10 µg/ml fusidic acid

10

Two types of trans-conjugants are expected from the second conjugation cycle:
one containing only the conjugative pAMβ1 plasmid and one containing both

pCRB96 and pAM β 1 plasmids.

Results

Table 8: First conjugation cycle.

	STRAINS	Colony Forming Units
DONORS	SH4174	10^7
RECIPIENTS	B39 (pCRB96)	10^9
TRANS-CONJUGATES	B39 (pCRB96-pAM β 1)	1000

5

Table 9: Second conjugation cycle.

	STRAINS	Colony Forming Units
DONORS	B39 (pCRB96-pAM β 1)	10^8
RECIPIENTS	TO60	10^8
TRANS-CONJUGANTS	TO60 (pAM β 1) TO60 (pCRB96-pAM β 1)	10^4 (pAM β 1) 50 (pCRB96-pAM β 1)

In the second conjugation cycle only 50 Colony Forming Units were subjected to co-mobilization of the pCRB96 plasmid by the pAM β 1 plasmid.

The phage resistance levels of the TO60 trans-conjugants (pCRB96-pAM β 1) were identical to those of B39.

The phage sensitivity levels of TO60 and TO60 (pAM β 1) were identical to those of TO03.

CLAIMS

1. *Streptococcus thermophilus* strains deposited at BCCM/LMG
(Gent/Belgium) P-18383 and P-18384.

5 2. Nucleic acid molecule having the sequence Seq. ID N°. 1.

3. Plasmid containing the nucleic acid molecule of claim 2.

4. Plasmid obtainable from a culture of *Streptococcus thermophilus* strain N.
P-18384 according to claim 1, having 3375 base pairs and a single restriction site
for each Accl, Ascl, Asnl, EcoRV, FokI, NotI, PstI, Pvull, XbaI nuclease.

10 5. Plasmid obtainable from a culture of *Streptococcus thermophilus* strain N.
P-18384 according to claim 1, having 6184 base pairs and a single restriction site
for each Aval, HindIII, KpnI, Pvul, SacI, SacII, Sall, Spel, SphI nuclease.

6. Plasmid obtainable from a culture of *Streptococcus thermophilus* strain N.
P-18383 according to claim 1, having 9515 base pairs and a single restriction site
for each Aval, NotI, PstI, Pvul, Pvull, SacI, SacII, Sall, SphI nuclease.

15 7. Microorganism containing the plasmid of claims 3-6.

8. Microorganism according to claim 7, selected from *Streptococcus thermophilus*, *Lactobacillus lactis*, *Bacillus subtilis*, *Escherichia coli*, *Lc. lactis* subsp. *lactis*, *Lc. lactis* subsp. *diacetylactis*, *Lc. Cremoris*, *Lb. delbrueckii* subsp. *Lactis*, *Lb. delbrueckii* subsp. *bulgaricus*, *Lb. delbrueckii* subsp. *delbrueckii*, *Lb. Helveticus*, *Lb. casei*.

20 9. Starter culture for milk fermentation, comprising a microorganism of claims
1, 7 or 8.


10. Use of a plasmid of claims 3-6, alone or in combination with a conjugative
plasmid, for conferring phage resistance to a bacterium.

1/5

FIGURE 1**A****B**


2/5

FIGURE 2



3/5

FIGURE 3



4/5

FIGURE 4





FIGURE 5



1 / 1

SEQUENCE LISTING

<110> ANIDRAL S.r.l.

<120> Phage-resistant microorganisms and gene determinants of phage resistance

<130> 5771M

<140>
<141>

<160> 1

<170> PatentIn Ver. 2.1

<210> 1
<211> 1111
<212> DNA
<213> Streptococcus thermophilus<400> 1
atggtaagg taaatttatt acttacatgg aatgtattca gtaatcctgt agctgattta 60
gatggacttg aaagtgtaga aattgataat aaacagttc aggttaaggc tggagatgtt 120
ctatttacta cttcatcaga aactccagaa gaagttggaa tgtcatctat gtggcttgg 180
aatgcagaca atatctatct taatagctt tggttggat atcgaccaac tattgaattt 240
gataaaatatt atcttagcgt catgttgagg tctgctccaa ttagaaagaa atttcagtt 300
cttacacaag gaatttctag atataacatt tcaaagaata aagttatgga aatgtctatt 360
cctgttccta gcattgaaga acaagaatta cttggagcat tttcaacaa cctcaatcaa 420
accatcgctc ttcatcagcg taagtttagt ttgttggaa agcagaaaaa agcgtttta 480
caaaaaatgt tccctaaaaa tggtgccaaa gttcctgaat tgcgattgc ggggtttgct 540
gacgattggg aagagcgtaa gttgggagat atttcctata aggtcaaaaga aaaaaataaa 600
actggtgagt ttacagaaac ttgaccaac tcagcagaat atggaattat taatcaacgt 660
gatttttta ataaagatat ttctaacgct aagaatctt ctggcttata ttagttaaa 720
aacatgttattttt ttgtatacaa tcctcgatt tcaaattttg ctccgggtgg accaattaaa 780
cgtaataaaat taggtagaac tggcgtaatg tcaccactat attatgtttt ccgtacacat 840
gatatcgata aaaattacct tgagaagtat tttgatactg tctactggca tcgattcatg 900
aaactaaacg gtgactcagg agtacgtgcc gatcgaaaaa caattaagga ctctgtttt 960
gttggaaatgc caattcctta tccaaacgatt gaagaacaag aaaaaatagg ttcatttttc 1020
aaacagtttag acgataactat cgctcttcat cagcgttaagt tagattgtt gaaagagcag 1080
aaaaaaggct ttttacaaaaa gatgtttgtt t 1111